OncoMatch/Clinical Trials/NCT05991908
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
Is NCT05991908 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Fludarabine, busulfan and melphalan and Fludarabine and Busulfan for acute myeloid leukemia.
Treatment: Fludarabine, busulfan and melphalan · Fludarabine and Busulfan — Fludarabine and busulfan becomes standard conditioning regimen for adult patients with acute myeloid leukemia (AML) or myelodysplasia syndrome (MDS). The overall relapse rate is 15\~20%. More recently, the investigators demonstrated that conditioning regimen with dual alkylating agents consistent of fludarabine, busulfan and melphalan achieved a low incidence of relapse (\<10%). This multiple-center randomize study is aim to compare the transplantation outcome in adult patients with AML/MDS undergoing allo-HSCT with conditioning regimen of Flu-Bu4 vs. FLu-Bu-Mel.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Disease stage
Required: Stage 1ST COMPLETE REMISSION
Lab requirements
Kidney function
no abnormal renal function
Liver function
no abnormal liver function
Cardiac function
no cardiac dysfunction
patients with abnormal liver function, renal function, respiratory or cardiac dysfunction
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify